Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TACC1
REST API REST API
Homo sapiens
TACC1 is differentially expressed in 327 experiments: 152 organism parts: liver, lung, ... (150 more);, 217 disease states: normal, colon carcinoma, ... (215 more);, 99 cell types 422 cell lines 54 compound treatments and 76 other conditions.
Orthologs Tacc1 (Rattus norvegicus)   TACC1 (Bos taurus)   ENSCING00000013819 (Ciona intestinalis)   tacc1 (Danio rerio)   tacc (Drosophila melanogaster)   Tacc1 (Mus musculus)   TACC1 (Gallus gallus)   TACC1 (Xenopus laevis)   TACC1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cell division, protein binding, cytoplasm, cell proliferation, neurogenesis, microtubule cytoskeleton, protein domain specific binding, cell cycle, microtubule organizing center, nucleus, microtubule cytoskeleton organization, cerebral cortex development, intermediate filament cytoskeleton, regulation of microtubule-based process, interkinetic nuclear migration
InterPro Term TACC
UniProt Accession O75410, B4E3H6, E5RFM9, E7ES82, E7ET87, E5RJG6, E5RIP3, E5RJU4, E7EVI4, E5RI10
Search EB-eye ENSG00000147526
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7224, E-GEOD-2549, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
MDA-MB-231
3
E-TABM-420, E-MTAB-62, E-GEOD-5823
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-3529, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
416 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18265, E-GEOD-20033, E-GEOD-18147
mesenchymal stem cell
2
E-GEOD-9894, E-GEOD-2248
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
mononuclear
2
E-GEOD-13987, E-GEOD-26672
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-TABM-15, E-MEXP-2280, ... (68 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-GEOD-3726, E-MTAB-62, E-MTAB-37, E-MTAB-57
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
melanoma
2
E-GEOD-7307, E-MTAB-62
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
osteosarcoma
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
2
E-MEXP-1331, E-MTAB-62
211 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-4668, E-GEOD-5741, E-GEOD-3720, E-GEOD-5824, ... (34 experiments)

Factor Value U/D Experiments
none
3
8
E-GEOD-6907, E-MEXP-1958, E-GEOD-5099, E-MEXP-1230, E-GEOD-412, ... (11 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
17beta-estradiol
1
2
4
E-GEOD-2292, E-GEOD-4006, E-GEOD-4668
valproic acid
1
E-GEOD-1615
hydroxyurea
1
E-GEOD-6431
HMB-PP (phosphoantigen)
1
E-MEXP-1601
48 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
58.98
1
1
E-TABM-325


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-19018, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-GEOD-22148, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-837, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 98 240
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.497 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM